Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy
2018-003221-29Phase 2Active
- Sponsor
- Xenon Pharmaceuticals
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Focal Onset Epilepsy and epilepsy comparing XEN1101 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Median percent change in monthly focal seizure frequency from baseline to double-blind period. Started Dec 2018; status: active.
02
Drugs
azetukalner
03
Conditions
Focal Onset Epilepsyepilepsy
Beyond the preview
Go deeper on 2018-003221-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003221-29.